Analytics

Equity Analytics

Equity Analytics/RPRX

RPRX

Royalty Pharma plc

Healthcare - US

Royalty Pharma plc (Nasdaq: RPRX) operates as the world's largest buyer of biopharmaceutical royalties and a leading funder of innovation across the life sciences industry; the company acquires royalties on sales of approved and development…

HQ: New York, NY, United States of Americawww.royaltypharma.com

USD69.31+0.49%vs prev. close

Performance

+2.99%

+17.49%

+18.28%

+74.45%

YTD

+79.37%

Valuation

P/E

45.0

EPS TTM

1.54

Dividend yield

1.36%

Size and risk

Market cap

$39.9B

Beta

0.36

Next earnings

Report date

EPS estimate

Revenue estimate

Peer comparison

Royalty Pharma
RPRX
Biotechnology
Mkt cap (USD bn)
39.9
P/E
45.0
Div yld
1.36%
1W
+3.0%
1M
+17.5%
3M
+18.3%
6M
+31.1%
1Y
+74.5%
YTD
+79.4%

Company	Ticker	Industry	Mkt cap (USD bn)	P/E	Div yld	1W	1M	3M	6M	1Y	YTD
Royalty Pharma	RPRX	Biotechnology	39.9	45.0	1.36%	+3.0%	+17.5%	+18.3%	+31.1%	+74.5%	+79.4%

Subscribe to Equity Analytics to compare RPRX with its closest peers

Sector-matched peer set with side-by-side valuation, dividend and performance over every window.

View plans

Ask Ashenden

Ask, then keep asking: it follows the conversation for 30 minutes, grounded in Ashenden research.

Built on Ashenden research and our own data. Answers are AI-generated: they can be wrong or incomplete — check anything you would act on.

Equity Analytics

RPRX

Price history

Next earnings

Peer comparison

Equity Analytics

RPRX

Price history

Next earnings

Peer comparison